Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197

PURPOSE: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant regimen. Doxorubicin and docetaxel (AT) is one of the most active cytotoxic regimens for metastatic breast cancer. The purpose of this trial was to determine whether adjuvant AT improved disease-free survival co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Goldstein, Lori J., O'Neill, Anne, Sparano, Joseph A., Perez, Edith A., Shulman, Lawrence N., Martino, Silvana, Davidson, Nancy E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2008
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2654376/
https://ncbi.nlm.nih.gov/pubmed/18678836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.7841
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados